Bookmark and Share

William T Carpenter
 

William T Carpenter M.D.

Academic Title: Professor
Primary Appointment: Psychiatry
Secondary Appointments: Pharmacology
wcarpent@mprc.umaryland.edu
Location: MPRC, P.O. Box 21247, Baltimore, MD 21228
Phone: (410) 402-7101
Fax: (410) 788-3837

Personal History:

Dr. Carpenter's major professional interest is severe mental illness, especially schizophrenia. His approach to the care and study of patients is within the context of a broad medical model integrating biological, psychological and social data as they pertain to diagnosis, treatment and etiology. He has made original and fundamental contributions in psychopathology, assessment methodology, testing of new treatments, research ethics, and translational science. He has authored over 400 clinical and scientific articles, book chapters and books.
 
Dr. Carpenter is Editor-in-Chief of Schizophrenia Bulletin, a journal with 2011 impact factor rating of 8.8 ranking it fourth out of 129 journals in the field.  He also serves on a number of editorial boards including the Archives of General Psychiatry.

Special professional assignments include service on the NIMH Intramural Research Program Board of Scientific Counselors and as a consultant and reviewer for NIMH and NIH on many topics. He chaired the NIMH Research Scientist Career Development Committee and the NIMH National Plan Committee on Treatment Research. Dr. Carpenter has been principle investigator on five types of NIMH Center grants and is currently focused on integrating an animal model, a human phenotype model, and a clinical trials model in developing novel treatments for cognition and negative symptoms of schizophrenia.

He provided expert testimony in the cases of the U.S. Government versus John Hinckley and the Commonwealth of Pennsylvania versus John DuPont and in 1989 was a member of the State Department delegation to inspect the political use of psychiatry in the Soviet Union. He is a recipient of major national and international research awards and was elected to the Institute of Medicine of the National Academy of Sciences in 1998.

Research Interests:

· Phenomenology of the psychoses
· Etiology, pathophysiology, and anatomy of schizophrenia
· Treatment of patients with schizophrenia
·  Integration of basic and clinical sciences
·  Research training and administration
·  Research ethics and informed consent

Publications:

Selected Publications (from over 400)

Carpenter WT, Strauss JS, Bartko JJ. A flexible system for the identification of schizophrenia. A report from the International Pilot Study of Schizophrenia. Science, 182:1275-1278, 1973.

Strauss JS, Carpenter WT Jr, Bartko JJ. The diagnosis and understanding of schizophrenia. Part III. Speculations on the processes that underlie schizophrenic symptoms and signs. Schizophr Bull. 1974 Winter;(11):61-9.

Strauss JS, Carpenter WT. Schizophrenia. Plenum Press, New York, 1981.

Carpenter WT, Heinrichs DW, Wagman AMI. Deficit and non-deficit forms of schizophrenia: The concept. Am J Psychiatry 145:578-583, 1988.

Carpenter WT, Hanlon TE, Heinrichs DW, Summerfelt A, Kirkpatrick B, Levine J, Buchanan RW. Continuous vs. targeted medication in schizophrenic outpatients: Outcome results. Am J Psychiatry 147:1138-1148, 1990.

Carpenter WT, Buchanan RW, Kirkpatrick B, Tamminga CA, Wood F. Strong inference, theory falsification, and the neuroanatomy of schizophrenia. Arch Gen Psychiatry 50:825-831, 1993.

Carpenter WT, Buchanan RW. Schizophrenia. N Eng J Med 330:681-690, 1994.

Carpenter WT, Schooler NR, Kane JM. The rationale and ethics of medication-free research in schizophrenia. Arch Gen Psychiatry 54:401-407, 1997.

Carpenter WT, Zito JM, Vitrai J, Volavka J. Hypothesis testing: is clozapine's superior efficacy dependent on moderate D2 receptor occupancy? Biol Psychiatry 43:79-83, 1998.

Carpenter WT. The schizophrenia ketamine challenge study debate. Biol Psychiatry 46:1081-1091, 1999.

Kirkpatrick B, Kopelowicz A, Buchanan RW, Carpenter WT. Assessing the efficacy of treatments for the deficit syndrome of schizophrenia. Neuropsychopharmacology 22(3):303-310, 2000.

Carpenter WT, Gold JM, Lahti AC, Queern CA, Conley RR, Bartko JJ, Kovnick J, Appelbaum PS. Decisional capacity for informed consent in schizophrenia research. Arch Gen Psychiatry, 57(6):533ï·"8, 2000.

Thaker GK and Carpenter WT. Advances in schizophrenia. Nature Medicine, 7(6):667-671, 2001.

Lahti AC, Holcomb HH, Medoff DR, Weiler MA, Tamminga CA, Carpenter WT Jr. Abnormal patterns of regional cerebral blood flow in schizophrenia with primary negative symptoms during an effortful auditory recognition task. Am J Psychiatry, 158(11):1797ï·"808, 2001.

Kirkpatrick B, Buchanan RW, Ross DE and Carpenter WT. A separate disease within the syndrome of schizophrenia. Archives of General Psychiatry, 58:165-171, 2001.

Carpenter WT and Gold JM. Another view of therapy for cognition in schizophrenia. (Editorial) Biological Psychiatry, 52:969-971, 2002.

Carpenter WT, Appelbaum PS, Levine RJ. The declaration of Helsinki and clinical trials: A focus on placebo-controlled trials in schizophrenia. American Journal of Psychiatry, 160:356-362, 2003.

Carpenter WT, Koenig JI, Bilbe G and Bischoff S. At Issue: A model for academic/industry collaboration. Schizophrenia Bulletin, 30(4):997-1004, 2004.

Carpenter WT. The schizophrenia paradigm: A hundred-year challenge [Editorial]. The Journal of Nervous and Mental Disease, 194(9):639-643, 2006.

Prentice KJ, Appelbaum PS, Conley RR, Carpenter WT. Maintaining Informed Consent Validity during Lengthy Research Protocols. IRB: Ethics & Human Research 29(6):1-6, 2007.

Buchanan RW, Javitt DC, Marder SR, Schooler NR, Gold JM, McMahon RP, Heresco-Levy U, Carpenter WT. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): The efficacy of glutamatergic agents for negative symptoms and cognitive impairments. American Journal of Psychiatry, 164:1593-1602, 2007.

Carpenter WT and Koenig JI. The Evolution of Drug Development in Schizophrenia: Past Issues and Future Opportunities. Neuropsychopharmacology. 33:2061-2079, 2008.

Rowland LM, Spieker EA, Francis A, Barker PB, Carpenter WT, Buchanan RW   White Matter Alterations in Deficit Schizophrenia. Neuropsychopharmacology, 34:1514-1522, 2009.

Fischer BA and Carpenter WT (2009) Will the Kraepelinian Dichotomy Survive DSM-V?  Neuropsychopharmacology, 34:2081–2087, 2009.

Carpenter WT, Bustillo JR, Thaker GK, van Os J, Krueger RF, Green MJ.  The Psychoses:  Cluster 3 of the proposed meta-structure for DSM-V and ICD-11. Psychological Medicine, 39(12):2025-2042, 2009.

William R. Keller, Bernard A. Fischer, William T. Carpenter, Jr.  Revisiting the Diagnosis of Schizophrenia: Where have we been and Where are We Going?  CNS Neuroscience & Therapeutics 00 (2010) 1–6.

Carpenter WT and van Os J.  Should Attenuated Psychosis Syndrome Be a DSM-5 Diagnosis? Am J Psychiatry 2011 168: 460-463.

Strauss GP, Allen DN, Miski P, Buchanan RW, Kirkpatrick B, Carpenter Jr., WT.  Differential patterns of premorbid social and academic deterioration in deficit and nondeficit schizophrenia. Schizophrenia Research, 2012 Mar;135(1-3):134-8.

Fischer BA, Keller WR, Arango C, Pearlson GD, McMahon RP, Meyer WA, Francis A, Kirkpatrick B, Carpenter WT, Buchanan RW.  Cortical structural abnormalities in deficit versus nondeficit schizophrenia. Schizophrenia Research, 2012 Apr;136(1-3):51-4.

Fusar-Poli P, Bechdolf A, Taylor MJ, Bonoldi I, Carpenter WT, Yung AR, McGuire P.  At risk for schizophrenic or affective psychoses?  A meta-analysis of DSM/ICD diagnostic outcomes in individuals at high clinical risk. Schizophrenia Bulletin, May 15, 2012 (epub ahead of print).

Carpenter WT.  The future of the schizophrenia construct and acquisition of new knowledge. Afterword In: Handbook of Schizophrenia Spectrum Disorders; Volumes I, II, and III.  Michael Ritsner, Editor.  Springer, New York, 2011.